Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Abilify Maintena

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

- PMLiVE

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Target action date for FDA decision is due on 15 November

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

- PMLiVE

Lundbeck gets US approval for migraine drug at heart of Alder takeover

US regulator clears CGRP inhibitor under Vyepti trade name

- PMLiVE

Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

Intra-Cellular soars on FDA approval of schizophrenia drug

Shares rocketed following the announcement

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

- PMLiVE

Otsuka presses on with Alzheimer’s agitation drug

Surprise announcement comes on the heels of phase 3 trial fail

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

- PMLiVE

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links